Merck & Co.
AWARDS
NEWS
Merck has announced positive results from its Phase III KEYNOTE-522 study on the use of KEYTRUDA alongside chemotherapy in high-risk early-stage triple-negative breast cancer.
Here’s a look at five companies that produced non-vaccine treatments for COVID-19.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
After reviewing available data, Bayer decided to abandon its Phase II development of eliapixant as the benefit-risk profile was not worthwhile.
The researchers believe Keytruda and possibly other anti-PD-1 checkpoint inhibitors might help the immune system track the last signs of HIV while also preventing HIV’s ability to hide.
After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.
JOBS
IN THE PRESS